Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer
نویسندگان
چکیده
منابع مشابه
HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease.
BACKGROUND Recent work detected for the first time a high-risk prostate cancer mutation, in homeobox B13 (HOXB13) among European-Americans. METHODS We further evaluated this G84E missense mutation (rs138213197) in two genetic association studies of prostate cancer: a family-based study of brothers and a case-control study of more aggressive disease (N = 2,665 total). We then calculated overal...
متن کاملHOXB13 mutations and prostate cancer in Poland
Recently, HOXB13 has been established as a prostate cancer susceptibility gene in North America, with a relative risk associated with a single missense mutation of about 20. Ewing et al., sequenced over 200 genes in a prostate cancer linkage region at 17q21-22 among 94 probands of prostate cancer families, and found a recurrent mutation in the HOXB13 gene (G84E) in four families. The mutation c...
متن کاملInherited genetic variant predisposes to aggressive but not indolent prostate cancer.
Autopsy studies suggest that most aging men will develop lesions that, if detected clinically, would be diagnosed as prostate cancer (PCa). Most of these cancers are indolent and remain localized; however, a subset of PCa is aggressive and accounts for more than 27,000 deaths in the United States annually. Identification of factors specifically associated with risk for more aggressive PCa is ur...
متن کاملCIP2A expression is increased in prostate cancer
BACKGROUND The CIP2A protein is a recently characterized oncoprotein which inhibits protein phosphatase 2A activity. Expression of CIP2A has been detected in several carcinomas, but its expression and significance in prostate cancer has not been examined so far. METHODS Expression of the CIP2A protein was studied using immunohistochemistry in prostate cancer (n = 59) and in benign prostatic h...
متن کاملSynergistic Anticancer Effect of Paclitaxel and Noscapine on Human Prostate Cancer Cell Lines
Paclitaxel is the one of the most common chemotherapeutic drugs used for the treatment of prostate cancer. However, its current clinical utility has been limited due to numerous serious side effects and drug resistance. Noscapine is an antitussive opium alkaloid that showed antitumor activity against a variety of cancer while has not exhibited severe side effects. This study investigates the a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2018
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-18-0444